COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I REGNREGN LY-CoVLY RemdesivirRMD
HCQ study #56 of 231
6/10 Late treatment study
Wang et al., medRxiv, doi:10.1101/2020.06.11.20128926 (Peer Reviewed)
Comorbidity and Sociodemographic determinants in COVID-19 Mortality in an US Urban Healthcare System
Source   PDF   Share   Tweet
Database analysis of 7,592 patients in NYC, showing adjusted HCQ mortality odds ratio OR 0.96, p = 0.82, and HCQ+AZ OR 0.94, p = 0.63

Wang et al., 6/10/2020, retrospective, database analysis, USA, North America, peer-reviewed, 3 authors.
risk of death, 5.8% lower, RR 0.94, p = 0.63, treatment 1866, control 5726, odds ratio converted to relative risk.
Details of all 231 studies    Meta analysis
Please send us corrections, updates, or comments.
Submit